Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M

PROTHENA CORP PUBLIC LTD CO

2022-Q2 EPS reported -$1.66 revenue$2,465,000

Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.
Total revenue $1.3M from BMS collaboration, down from $60.1M in Q2 2021 which included Roche revenue.
Cash and restricted cash $510.1M at June 30, 2022; no debt.
FDA Fast Track granted for PRX012 (anti-Aβ antibody for Alzheimer's); topline Phase 1 data for PRX005 expected by year-end 2022.
Full-year 2022 net cash used in operations and investing expected $120-$132M; year-end cash ~$454M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.